Global Consensus Renames PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS)

A major shift in the nomenclature of one of the most prevalent endocrine and metabolic disorders is underway. Following a multi-year global consensus process, the condition traditionally known as polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS).¹ The decision, published in The Lancet and supported by a coalition of 56 international organizations, aims to address long-standing inaccuracies that have hindered clinical diagnosis, research funding, and patient care.

The Rationale for Change

Professor Helena Teede of Monash University, a lead architect of the change, emphasized the necessity of the update for patient clarity and clinical accuracy.² “What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” Teede stated. The new nomenclature is designed to align diagnostic criteria with the underlying pathophysiology of the disorder, which affects approximately 170 million women worldwide.

Research highlighted in the consensus report that features of the condition can be metabolic, reproductive, psychological, and dermatoligical. The previous name focused on only one organ, and this contributed to knowledge gaps, delayed diagnosis, and frequently obscured the broader metabolic and endocrine complexities of the condition.

“It is fantastic that the new name now leads with hormones and recognizes the metabolic dimension of the condition,” stated Rachel Morman, chair of the UK advocacy group Verity, noting that the name PCOS did not represent the condition’s true nature. “This shift will reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is.”

For manufacturers in the nutraceutical space, this rebranding highlights the systemic nature of the syndrome. PMOS is characterized by hormonal fluctuations that impact weight management, metabolic function, mental health, and dermatological conditions, in addition to reproductive health.

A Rigorous Consensus Process

The renaming was the result of a 14-year collaborative effort between organizations and individuals with lived experience with the condition. The process utilized iterative global surveys, involving over 14,360 respondents with PCOS and multidisciplinary health professionals.

The renaming initiative prioritized scientific accuracy and the avoidance of stigma. Key outcomes of the Delphi method workshops indicated a strong preference for a name that reflected the multisystem pathophysiology of the disorder, facilitated diagnosis, and optimized care.

Strategic Implications for the Industry

The transition to PMOS signals a broadening of the market categories relevant to this demographic. While previous product development may have focused heavily on fertility or cycle regulation, the new nomenclature may validate a more holistic approach.

One recent botanical highlighted in PMOS research is shatavari, with studies demonstrating its hormonal adaptogen properties, normalizing dysregulated signaling and ovarian function in women aged 20-25 with the condition, for example, and helping restore key hormones in perimenopausal women.³

Other nutrients such as folic acid, omega-3s and CoQ10 have also been noted for women dealing with the condition.⁴

Implementation and Transition

A three-year transition period has been established to allow for the integration of the new terminology into clinical practice, health systems, and disease classification codes. The PMOS name will be fully implemented in the 2028 International Guideline update. During this window, an international education campaign will be conducted to align researchers, healthcare providers, and regulatory bodies with the updated framework.

For the nutraceutical industry, this period offers an opportunity to align marketing materials and educational content with the new scientific standard.

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Teede HJ, Khomami MB, Morman R, Laven JSE, Joham AE, Costello MF, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online May 12, 2026. doi: 10.1016/S0140-6736(26)00717-8
2. Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. May 12, 2026. Accessed May 13, 2026. https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change
3. Reilly MK. Shatavari: The Next Breakout Botanical. May 11, 2026. Accessed May 13, 2026. https://www.nutritionaloutlook.com/view/shatavari-the-next-breakout-botanical
4. Krawiec S. How diet and dietary supplements during preconception may impact fertility. December 16, 2025. Accessed May 13, 2026. https://www.nutritionaloutlook.com/view/how-diet-and-dietary-supplements-during-preconception-may-impact-fertility